140 related articles for article (PubMed ID: 35306231)
1. Multiagent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial.
Hill CS; Rosati L; Wang H; Tsai HL; He J; Hacker-Prietz A; Laheru DA; Zheng L; Sehgal S; Bernard V; Le DT; Pawlik TM; Weiss MJ; Narang AK; Herman JM
Pract Radiat Oncol; 2022; 12(6):511-523. PubMed ID: 35306231
[TBL] [Abstract][Full Text] [Related]
2. Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma.
Herman JM; Chang DT; Goodman KA; Dholakia AS; Raman SP; Hacker-Prietz A; Iacobuzio-Donahue CA; Griffith ME; Pawlik TM; Pai JS; O'Reilly E; Fisher GA; Wild AT; Rosati LM; Zheng L; Wolfgang CL; Laheru DA; Columbo LA; Sugar EA; Koong AC
Cancer; 2015 Apr; 121(7):1128-37. PubMed ID: 25538019
[TBL] [Abstract][Full Text] [Related]
3. Preoperative treatment with mFOLFIRINOX or Gemcitabine/Nab-paclitaxel +/- isotoxic high-dose stereotactic body Radiation Therapy (iHD-SBRT) for borderline resectable pancreatic adenocarcinoma (the STEREOPAC trial): study protocol for a randomised comparative multicenter phase II trial.
Bouchart C; Navez J; Borbath I; Geboes K; Vandamme T; Closset J; Moretti L; Demetter P; Paesmans M; Van Laethem JL
BMC Cancer; 2023 Sep; 23(1):891. PubMed ID: 37735634
[TBL] [Abstract][Full Text] [Related]
4. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy.
Hill C; Sehgal S; Fu W; Hu C; Reddy A; Thompson E; Hacker-Prietz A; Le D; De Jesus-Acosta A; Lee V; Zheng L; Laheru DA; Burns W; Weiss M; Wolfgang C; He J; Herman JM; Meyer J; Narang A
Cancer Med; 2022 Apr; 11(7):1659-1668. PubMed ID: 35142085
[TBL] [Abstract][Full Text] [Related]
5. AGITG MASTERPLAN: a randomised phase II study of modified FOLFIRINOX alone or in combination with stereotactic body radiotherapy for patients with high-risk and locally advanced pancreatic cancer.
Oar A; Lee M; Le H; Wilson K; Aiken C; Chantrill L; Simes J; Nguyen N; Barbour A; Samra J; Sjoquist KM; Moore A; Espinoza D; Gebski V; Yip S; Chu J; Kneebone A; Goldstein D
BMC Cancer; 2021 Aug; 21(1):936. PubMed ID: 34412605
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity.
Hill CS; Rosati LM; Hu C; Fu W; Sehgal S; Hacker-Prietz A; Wolfgang CL; Weiss MJ; Burkhart RA; Hruban RH; De Jesus-Acosta A; Le DT; Zheng L; Laheru DA; He J; Narang AK; Herman JM
Ann Surg Oncol; 2022 Apr; 29(4):2456-2468. PubMed ID: 35129721
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes of a multicenter phase 2 study investigating gemcitabine and stereotactic body radiation therapy in locally advanced pancreatic cancer.
Rao AD; Sugar EA; Chang DT; Goodman KA; Hacker-Prietz A; Rosati LM; Columbo L; O'Reilly E; Fisher GA; Zheng L; Pai JS; Griffith ME; Laheru DA; Iacobuzio-Donahue CA; Wolfgang CL; Koong A; Herman JM
Pract Radiat Oncol; 2016; 6(6):417-424. PubMed ID: 27552809
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome.
Teriaca MA; Loi M; Suker M; Eskens FALM; van Eijck CHJ; Nuyttens JJ
Radiother Oncol; 2021 Feb; 155():232-236. PubMed ID: 33217500
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 Dose Escalation Study of SBRT Using 3 Fractions for Locally Advanced Pancreatic Cancer.
Reyngold M; Karam SD; Hajj C; Wu AJ; Cuaron J; Lobaugh S; Yorke ED; Dickinson S; Jones B; Vinogradskiy Y; Shukla-Dave A; Do RKG; Sigel C; Zhang Z; Crane CH; Goodman KA
Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):53-63. PubMed ID: 36918130
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiation therapy with concurrent full-dose gemcitabine for locally advanced pancreatic cancer: a pilot trial demonstrating safety.
Gurka MK; Collins SP; Slack R; Tse G; Charabaty A; Ley L; Berzcel L; Lei S; Suy S; Haddad N; Jha R; Johnson CD; Jackson P; Marshall JL; Pishvaian MJ
Radiat Oncol; 2013 Mar; 8():44. PubMed ID: 23452509
[TBL] [Abstract][Full Text] [Related]
11. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
[TBL] [Abstract][Full Text] [Related]
12. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113).
Hartlapp I; Valta-Seufzer D; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens UM; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Anger F; Germer CT; Stang A; Kimmel B; Heinemann V; Kunzmann V;
ESMO Open; 2022 Aug; 7(4):100552. PubMed ID: 35970013
[TBL] [Abstract][Full Text] [Related]
13. Long-term outcomes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma.
Mellon EA; Hoffe SE; Springett GM; Frakes JM; Strom TJ; Hodul PJ; Malafa MP; Chuong MD; Shridhar R
Acta Oncol; 2015 Jul; 54(7):979-85. PubMed ID: 25734581
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes and prognostic factors of stereotactic body radiation therapy combined with gemcitabine plus capecitabine for locally advanced unresectable pancreatic cancer.
Shen ZT; Zhou H; Li AM; Ji XQ; Jiang CC; Yuan X; Li B; Zhu XX; Huang GC
J Cancer Res Clin Oncol; 2020 Feb; 146(2):417-428. PubMed ID: 31667573
[TBL] [Abstract][Full Text] [Related]
15. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of different neoadjuvant chemotherapy regimens with or without stereotactic body radiation therapy for borderline resectable pancreatic cancer: study protocol of a prospective, randomized phase II trial (BRPCNCC-1).
Gao S; Zhu X; Shi X; Cao K; Bian Y; Jiang H; Wang K; Guo S; Zhang H; Jin G
Radiat Oncol; 2019 Mar; 14(1):52. PubMed ID: 30917842
[TBL] [Abstract][Full Text] [Related]
17. Feasibility, safety, and efficacy of stereotactic body radiotherapy combined with intradermal heat-killed mycobacterium obuense (IMM-101) vaccination for non-progressive locally advanced pancreatic cancer, after induction chemotherapy with (modified)FOLFIRINOX - The LAPC-2 trial.
van 't Land FR; Latifi D; Moskie M; Homs MYV; Bosscha K; Bonsing BA; Mieog SD; van der Harst E; Coene PLO; Wijsman JH; van der Schelling GP; Groot Koerkamp B; Nuyttens JJ; van Eijck CHJ;
Radiother Oncol; 2023 Jun; 183():109541. PubMed ID: 36813171
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of concurrent stereotactic body radiotherapy and nelfinavir for locally advanced borderline or unresectable pancreatic adenocarcinoma.
Lin C; Verma V; Ly QP; Lazenby A; Sasson A; Schwarz JK; Meza JL; Are C; Li S; Wang S; Hahn SM; Grem JL
Radiother Oncol; 2019 Mar; 132():55-62. PubMed ID: 30825970
[TBL] [Abstract][Full Text] [Related]
19. Gemcitabine chemotherapy and single-fraction stereotactic body radiotherapy for locally advanced pancreatic cancer.
Schellenberg D; Goodman KA; Lee F; Chang S; Kuo T; Ford JM; Fisher GA; Quon A; Desser TS; Norton J; Greco R; Yang GP; Koong AC
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):678-86. PubMed ID: 18395362
[TBL] [Abstract][Full Text] [Related]
20. Lymphocyte-Sparing Effect of Stereotactic Body Radiation Therapy in Patients With Unresectable Pancreatic Cancer.
Wild AT; Herman JM; Dholakia AS; Moningi S; Lu Y; Rosati LM; Hacker-Prietz A; Assadi RK; Saeed AM; Pawlik TM; Jaffee EM; Laheru DA; Tran PT; Weiss MJ; Wolfgang CL; Ford E; Grossman SA; Ye X; Ellsworth SG
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):571-9. PubMed ID: 26867885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
